Security
Roivant Sciences Ltd. Common Shares · ROIV
ROIVNASDAQCommon stockCurrentCIK 1635088Updated Nov 1, 2026
ROIV price & chart
Loading TradingView…
NASDAQ:ROIV on TradingView ↗About the company
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.
In the news
No coverage from other publishers is available.
Recent filings
4 filing
SCHEDULE 13G/A - filed by BlackRock, Inc. regarding Roivant Sciences Ltd.
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13D/A - filed by Roivant Sciences Ltd. regarding Arbutus Biopharma Corp
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q1 2023 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ASSETS | |||||
| AssetsUSD | — | 5,436,940,000Source | 7,222,482,000Source | 2,389,604,000Source | 2,585,129,000Source |
| Property, Plant and Equipment, NetUSD | — | 12,056,000Source | 15,322,000Source | 39,086,000Source | 25,905,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | 144,881,000Source | — |
| Current assets: | |||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 2,715,411,000Source | 6,494,953,000Source | 1,676,813,000Source | 2,060,400,000Source |
| Inventory, NetUSD | — | — | — | 2,761,000Source | — |
| Assets, CurrentUSD | — | 5,000,064,000Source | 6,731,828,000Source | 1,798,587,000Source | 2,146,523,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 89,021,000Source | 44,002,000Source | 53,251,000Source | 61,044,000Source |
| Other Assets, NoncurrentUSD | — | 32,860,000Source | 37,701,000Source | 49,482,000Source | 16,092,000Source |
| LIABILITIES AND EQUITY | |||||
| LiabilitiesUSD | — | 249,742,000Source | 773,953,000Source | 782,017,000Source | 523,695,000Source |
| Stockholders’ equity: | |||||
| Common Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | — | 4,562,107,000Source | 5,396,492,000Source | 4,933,137,000Source | 4,421,614,000Source |
| Retained Earnings (Accumulated Deficit)USD | — | 116,060,000Source | 576,172,000Source | -3,772,754,000Source | -2,763,724,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 9,438,000Source | -4,083,000Source | -2,617,000Source | -946,000Source |
| Stockholders' Equity Attributable to ParentUSD | — | 4,687,605,000Source | 5,968,581,000Source | 1,157,766,000Source | 1,656,944,000Source |
| Liabilities and EquityUSD | — | 5,436,940,000Source | 7,222,482,000Source | 2,389,604,000Source | 2,585,129,000Source |
| Current liabilities: | |||||
| Liabilities, CurrentUSD | — | 149,411,000Source | 266,758,000Source | 272,448,000Source | 184,367,000Source |
| Operating Lease, Liability, CurrentUSD | — | 9,842,000Source | 8,966,000Source | 11,693,000Source | 11,398,000Source |
| Accounts Payable, CurrentUSD | — | 23,691,000Source | 14,029,000Source | 37,830,000Source | 34,583,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 90,328,000Source | 45,020,000Source | 53,476,000Source | 62,468,000Source |
| Other Liabilities, NoncurrentUSD | — | 22,000Source | 2,493,000Source | 17,032,000Source | 8,183,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | 499,593,000Source | 479,948,000Source | 449,821,000Source | 381,999,000Source |
| Additional Financial Items | |||||
| Accrued Liabilities, CurrentUSD | — | 114,294,000Source | 119,417,000Source | 167,129,000Source | 127,531,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 4,886,891,000Source | 6,494,953,000Source | — | — |
| Deferred Revenue, CurrentUSD | — | — | 4,168,000Source | 12,444,000Source | 10,147,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | — | — | 13,740,000Source |
| Long-term DebtUSD | — | — | — | 375,515,000Source | 210,025,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | 40,720,000Source | 0Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | 210,025,000Source |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD | — | — | — | 0Source | 22,491,000Source |
| Dividends Payable, Current | —Source | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 118,075,000Source | 5,072,665,000Source | -279,924,000Source | -331,118,000Source | -273,911,000Source | 57,490,000Source | -356,734,000Source | 4,231,206,000Source | -1,115,463,000Source | -924,116,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 1,098,000Source | 4,883,000Source | 14,071,000Source | 22,036,000Source | 18,857,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 82,178,000Source | 50,191,000Source | 289,029,000Source | 199,627,000Source | 217,781,000Source | 564,956,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -204,383,000Source | -192,829,000Source | -839,451,000Source | -765,268,000Source | -843,393,000Source | -677,729,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -1,085,716,000Source | -965,000Source | -1,766,291,000Source | 5,203,623,000Source | -44,269,000Source | 303,295,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -79,000Source | -8,592,000Source | -702,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 4,035,000Source | 965,000Source | 4,599,000Source | 1,382,000Source | 12,690,000Source | 17,436,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 208,293,000Source | 648,385,000Source | — | 0Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -187,768,000Source | -660,616,000Source | -1,219,794,000Source | 419,364,000Source | 499,462,000Source | 306,792,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,477,052,000Source | -857,150,000Source | -3,824,789,000Source | 4,858,335,000Source | -381,919,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | 2,725,661,000Source | 6,506,189,000Source | 1,692,115,000Source | 2,074,034,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 5,963,000Source | 10,268,000Source | 5,303,000Source | 5,535,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 61,910,000Source | 12,354,000Source | 5,128,000Source | 916,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | — | 6,281,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 564,956,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 4,886,891,000Source | 6,494,953,000Source | — | — |
| Deconsolidation, Gain (Loss), AmountUSD | — | — | — | 0Source | — | 17,354,000Source | — | — | 3,108,000Source | 32,772,000Source | 29,276,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | -21,314,000Source | -10,467,000Source | 48,375,000Source | -45,849,000Source | -19,125,000Source | 15,226,000Source | 55,186,000Source | -47,973,000Source | -20,815,000Source | -87,291,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -8,848,000Source | 0Source | — | — |
| General and Administrative ExpenseUSD | — | — | 141,545,000Source | 128,172,000Source | 202,881,000Source | 88,576,000Source | 134,019,000Source | 99,892,000Source | 591,410,000Source | 416,133,000Source | — | 775,033,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -157,639,000Source | 5,154,466,000Source | -187,101,000Source | -218,226,000Source | — | 6,049,000Source | -545,166,000Source | 4,662,703,000Source | -1,123,591,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -208,945,000Source | 5,131,180,000Source | -236,841,000Source | -244,642,000Source | -273,900,000Source | -31,603,000Source | -729,764,000Source | 4,546,353,000Source | -1,230,024,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 327,020,000Source | -58,515,000Source | -43,083,000Source | -86,476,000Source | — | 89,093,000Source | 373,030,000Source | -315,147,000Source | 114,561,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | 327,020,000Source | -58,282,000Source | -43,083,000Source | -86,101,000Source | — | 89,248,000Source | 373,185,000Source | -313,777,000Source | 114,561,000Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | -25,568,000Source | 22,365,000Source | 12,458,000Source | 3,236,000Source | 4,649,000Source | 11,963,000Source | 48,174,000Source | 21,503,000Source | 5,190,000Source | 369,000Source |
| Investment Income, InterestUSD | — | — | 61,851,000Source | — | 69,773,000Source | — | 48,322,000Source | — | 258,375,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 169,381,000Source | 5,096,184,000Source | -230,184,000Source | -304,327,000Source | -223,355,000Source | 95,297,000Source | -171,981,000Source | 4,348,926,000Source | -1,009,030,000Source | -845,262,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -51,306,000Source | -23,519,000Source | -49,740,000Source | -26,791,000Source | -50,556,000Source | -37,807,000Source | -184,753,000Source | -117,720,000Source | -106,433,000Source | -78,854,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -171,981,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 283,399,000Source | 236,517,000Source | 346,188,000Source | 217,539,000Source | 287,092,000Source | 220,612,000Source | 1,142,734,000Source | 884,091,000Source | 1,236,598,000Source | 1,406,928,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -2,816,000Source | 2,112,000Source | -1,453,000Source | -1,530,000Source | -11,208,000Source | -3,608,000Source | -10,721,000Source | -13,562,000Source | 15,808,000Source | -3,435,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 199,822,000Source | 311,981,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 0Source | — | 0Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 30,057,000Source | 2,271,000Source | 49,597,000Source | 54,314,000Source | 2,814,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 9,018,000Source | 15,562,000Source | 4,475,000Source | 3,648,000Source | 2,170,000Source | 7,990,000Source | 29,053,000Source | 32,713,000Source | 61,280,000Source | 55,286,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 600,506,000Source | — |
| Operating Income (Loss)USD | — | — | -274,381,000Source | 5,127,455,000Source | -341,713,000Source | -213,891,000Source | -284,922,000Source | -102,235,000Source | -1,003,294,000Source | 4,497,032,000Source | -1,175,318,000Source | -1,351,642,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -2,816,000Source | 2,112,000Source | -1,453,000Source | -1,530,000Source | -11,208,000Source | -3,608,000Source | -10,721,000Source | -13,562,000Source | 15,808,000Source | -3,435,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -234,513,000Source | 5,153,545,000Source | -224,383,000Source | -241,406,000Source | -269,262,000Source | -19,640,000Source | -681,590,000Source | 4,567,856,000Source | -1,224,834,000Source | -923,747,000Source |
| Income Tax Expense (Benefit)USD | — | — | -25,568,000Source | 22,365,000Source | 12,458,000Source | 3,236,000Source | 4,649,000Source | 11,963,000Source | 48,174,000Source | 21,503,000Source | 5,190,000Source | 369,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -51,306,000Source | -23,519,000Source | -49,740,000Source | -26,791,000Source | -50,556,000Source | -37,807,000Source | -184,753,000Source | -117,720,000Source | -106,433,000Source | -78,854,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 169,381,000Source | 5,096,184,000Source | -230,184,000Source | -304,327,000Source | -223,355,000Source | 95,297,000Source | -171,981,000Source | 4,348,926,000Source | -1,009,030,000Source | -845,262,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.23Source | 6.37Source | -0.31Source | -0.4Source | -0.33Source | 0.13Source | -0.24Source | 5.55Source | -1.42Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | 0.23Source | 6.03Source | -0.31Source | -0.4Source | -0.33Source | 0.12Source | -0.24Source | 5.23Source | -1.42Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 722,716,168Source | 800,587,716Source | 735,470,796Source | 770,227,849Source | 680,286,922Source | 735,816,536Source | 725,395,624Source | 783,248,906Source | 712,791,115Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 722,716,168Source | 844,461,685Source | 735,470,796Source | 770,227,849Source | 680,286,922Source | 781,627,601Source | 725,395,624Source | 831,049,444Source | 712,791,115Source | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 48,174,000Source | 21,503,000Source | 5,190,000Source | 369,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | -21,314,000Source | -10,467,000Source | 48,375,000Source | -45,849,000Source | -19,125,000Source | 15,226,000Source | 55,186,000Source | -47,973,000Source | -20,815,000Source | -87,291,000Source |
| General and Administrative ExpenseUSD | — | — | 141,545,000Source | 128,172,000Source | 202,881,000Source | 88,576,000Source | 134,019,000Source | 99,892,000Source | 591,410,000Source | 416,133,000Source | — | 775,033,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -157,639,000Source | 5,154,466,000Source | -187,101,000Source | -218,226,000Source | — | 6,049,000Source | -545,166,000Source | 4,662,703,000Source | -1,123,591,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -208,945,000Source | 5,131,180,000Source | -236,841,000Source | -244,642,000Source | -273,900,000Source | -31,603,000Source | -729,764,000Source | 4,546,353,000Source | -1,230,024,000Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.22Source | 6.44Source | -0.25Source | -0.28Source | — | 0.01Source | -0.75Source | 5.95Source | -1.58Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | -0.22Source | 6.1Source | -0.25Source | -0.28Source | — | 0.01Source | -0.75Source | 5.61Source | -1.58Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 327,020,000Source | -58,515,000Source | -43,083,000Source | -86,476,000Source | — | 89,093,000Source | 373,030,000Source | -315,147,000Source | 114,561,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | 327,020,000Source | -58,282,000Source | -43,083,000Source | -86,101,000Source | — | 89,248,000Source | 373,185,000Source | -313,777,000Source | 114,561,000Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 27,968,000Source | 7,041,000Source |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | — | — | — | 369,000Source |
| Investment Income, InterestUSD | — | — | 61,851,000Source | — | 69,773,000Source | — | 48,322,000Source | — | 258,375,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -171,981,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 283,399,000Source | 236,517,000Source | 346,188,000Source | 217,539,000Source | 287,092,000Source | 220,612,000Source | 1,142,734,000Source | 884,091,000Source | 1,236,598,000Source | 1,406,928,000Source |
| Research and Development ExpenseUSD | — | — | 141,595,000Source | 108,148,000Source | 143,073,000Source | 114,790,000Source | 152,919,000Source | 120,507,000Source | 550,413,000Source | 439,909,000Source | 525,215,000Source | 483,035,000Source |
Filing attachments
ef20084121_ex99-1.htm · 8-K · 2026-10-21
Exhibit 99.1 Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase 3 trials comprising the CLARITY program in NIU Median time to treatment failure for brepocitinib patients was greater than 48 weeks in both…
Read attachment ↗ef20083304_ex99-1.htm · SCHEDULE 13D/A · 2026-10-05
Exhibit 99.1 Covered Persons Roivant has a board of directors (such individuals, collectively, the "Covered Persons"). The name, present principal occupation and country of citizenship of each of the Covered Persons is set forth below, along with the principal business address of the employer of each of the Covered Persons. Name Principal Business Present Principal Occupation …
Read attachment ↗ef20081686_ex99-1.htm · 8-K · 2026-09-08
EX-99.1 2 ef20081686_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever reported PVR…
Read attachment ↗ef20081283_ex99-1.htm · 8-K · 2026-08-28
EX-99.1 2 ef20081283_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 LISRAYA (brepocitinib) Approved for Treatment of Patients with Dermatomyositis August 28, 2026 For investor audiences only Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in …
Read attachment ↗ef20081229_ex99-1.htm · 8-K · 2026-08-27
EX-99.1 2 ef20081229_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune disease LISRAYA is a once-daily pill that directly targets key immune pathways implicated in dermatomyositis pathogenesis LISRAYA demonstrated robust efficacy on multipl…
Read attachment ↗roiv-20260331xex41.htm · 10-K · 2026-05-20
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 31, 2026, Roivant Sciences Ltd. (the “Company,” “Roivant” or “we”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): common shares. The following description of the common shares is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference …
Read attachment ↗